Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | PDE2A | O00408 | 6/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NT5E | P21589 | 8/20 | 0.44 |
| ▸ | CD99 | P14209 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19366657 | 1.00 | LMNA (0.57) | LMNATP53PDE2AADORA3ADORA2A | |
| SCHEMBL10026370 | 1.00 | LMNA (0.57) | LMNATP53PDE2AADORA3ADORA2A | |
| SCHEMBL10026368 | 1.00 | LMNA (0.57) | LMNATP53PDE2AADORA3ADORA2A | |
| SCHEMBL12139442 | 0.89 | PDE2A (0.67) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL19766028 | 0.89 | NT5E (0.49) | LMNATP53PDE2AADORA3ADORA2A | |
| SCHEMBL10026402 | 0.89 | PDE2A (0.67) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL19766069 | 0.89 | NT5E (0.49) | LMNATP53PDE2AADORA3ADORA2A | |
| SCHEMBL12139441 | 0.89 | PDE2A (0.67) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL10026378 | 0.89 | PDE2A (0.67) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL25688876 | 0.85 | TYMP (0.45) | LMNATP53PDE2AADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648188-B2 | Preparation of 2-chloro-9-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-adenine | SCINOPHARM TAIWAN, LTD. (TW) | 2014-02-11 | — | — | US | disclosed |
| US-20120010397-A1 | Preparation of 2-chloro-9-(2'-deoxy-2'-fluoro-Beta-D-arabinofuranosyl)-adenine | SCINOPHARM TAIWAN LTD. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010397-A1 | Preparation of 2-chloro-9-(2'-deoxy-2'-fluoro-Beta-D-arabinofuranosyl)-adenine | HPRT1, TYMP, MTAP | LMNA 1315/4885TP53 425/4885PDE2A 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.